<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>More intensive <z:mp ids='MP_0002055'>diabetes</z:mp> control prevents <z:e sem="disease" ids="C0155765" disease_type="Disease or Syndrome" abbrv="">microangiopathy</z:e> in patients with both type 1 <z:mp ids='MP_0002055'>diabetes</z:mp> and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>The data related to prevention of macrovascular disease in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> are controversial </plain></SENT>
<SENT sid="2" pm="."><plain>The data confirming benefit of the HbA(1c) levels below 6.5% came almost exclusively from epidemiological studies </plain></SENT>
<SENT sid="3" pm="."><plain>The following article reviews the data from five large clinical randomized trials which compared the more intensive <z:chebi fb="105" ids="17234">glucose</z:chebi> lowering strategy with the standard <z:chebi fb="0" ids="35526">antidiabetic</z:chebi> treatment i.e. UKPDS, PROactive, ACCORD, ADVANCE and VADT </plain></SENT>
<SENT sid="4" pm="."><plain>Metaanalysis of five trials showed a highly significant reduction of the incidence of non fatal <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> [OR 0.84 (95% CI 0.75-0.93), p = 0.001] in patients with intensive glycemic control </plain></SENT>
<SENT sid="5" pm="."><plain>No significant differences were observed by combined analysis for the non-fatal <z:hpo ids='HP_0001297'>stroke</z:hpo>, cardiovascular mortality and <z:hpo ids='HP_0000001'>all</z:hpo>-cause mortality between the compared groups </plain></SENT>
<SENT sid="6" pm="."><plain>The reason for the discordance of the results of the epidemiological and interventional studies is not clear </plain></SENT>
<SENT sid="7" pm="."><plain>The possible explanations could include short duration of the trials to show effect of <z:chebi fb="105" ids="17234">glucose</z:chebi> lowering, as well as attenuating of the beneficial effect of better glycemic control by increased <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo>-related mortality in patients with preexisting <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> </plain></SENT>
</text></document>